GSK plc reported £32.7 billion in total sales for 2025, a 4% increase year-over-year, driven by strong growth in Specialty Medicines, including an 11% rise in HIV sales. The company also expects a 3-5% turnover growth for 2026 with an increased dividend of 70p per share announced for the coming year.